BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)

clipboard-pencil

About the study

The purpose of this study is to describe the natural history and progression of patients diagnosed with PH1, and to characterize the long-term real-world safety and effectiveness of lumasiran.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:

Documented diagnosis of PH1, per physician's determination

EXCLUSION CRITERIA

Exclusion Criteria:

Currently enrolled in a clinical trial for any investigational agent

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.

Study’s details


Contition
Primary Hyperoxaluria Type 1
Participants needed
200
Est. Completion Date
Sep 30, 2028
Treatment type
Observational

Sponsor
Alnylam Pharmaceuticals
ClinicalTrials.gov identifier
NCT04982393
Study number
ALN-GO1-007

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.